169 related articles for article (PubMed ID: 11020006)
21. Reply to: Comments on "An open-label randomised-controlled trial of azathioprine vs. mycophenolate mofetil for the induction of remission in treatment-naive autoimmune hepatitis".
Snijders RJALM; Stoelinga AEC; van Hoek B; Drenth JPH
J Hepatol; 2024 Jul; 81(1):e43-e44. PubMed ID: 38554845
[No Abstract] [Full Text] [Related]
22. Use of immunomodulary agents is difficult in treating autoimmune hepatitis patients.
Gordon FD; Simpson M
J Clin Gastroenterol; 2004 Oct; 38(9):729-30. PubMed ID: 15365394
[No Abstract] [Full Text] [Related]
23. Iatrogenic immunodeficiency-associated lymphoproliferative disease of the Hodgkin lymphoma-like variant in a patient treated with mycophenolate mofetil for autoimmune hepatitis.
Adams B; Lazarchick J; Medina AM; Willner IR; Neville B; Murphy E; Stuart R; Costa LJ
Am J Hematol; 2010 Aug; 85(8):627-9. PubMed ID: 20658594
[No Abstract] [Full Text] [Related]
24. Seronegative autoimmune hepatitis presenting after diagnosis of coeliac disease: a case report.
Quail MA; Russell RK; Bellamy C; Mieli-Vergani G; Gillett PM
Eur J Gastroenterol Hepatol; 2009 May; 21(5):576-9. PubMed ID: 19318969
[TBL] [Abstract][Full Text] [Related]
25. Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy.
Inductivo-Yu I; Adams A; Gish RG; Wakil A; Bzowej NH; Frederick RT; Bonacini M
Clin Gastroenterol Hepatol; 2007 Jul; 5(7):799-802. PubMed ID: 17509945
[TBL] [Abstract][Full Text] [Related]
26. A real-world study focused on the long-term efficacy of mycophenolate mofetil as first-line treatment of autoimmune hepatitis.
Zachou K; Gatselis NK; Arvaniti P; Gabeta S; Rigopoulou EI; Koukoulis GK; Dalekos GN
Aliment Pharmacol Ther; 2016 May; 43(10):1035-47. PubMed ID: 26991238
[TBL] [Abstract][Full Text] [Related]
27. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory or intolerant to conventional therapy.
Sharzehi K; Huang MA; Schreibman IR; Brown KA
Can J Gastroenterol; 2010 Oct; 24(10):588-92. PubMed ID: 21037986
[TBL] [Abstract][Full Text] [Related]
28. Evolving new therapies of autoimmune hepatitis.
Vierling JM; Flores PA
Clin Liver Dis; 2002 Aug; 6(3):825-50, ix. PubMed ID: 12362583
[TBL] [Abstract][Full Text] [Related]
29. A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis.
Hlivko JT; Shiffman ML; Stravitz RT; Luketic VA; Sanyal AJ; Fuchs M; Sterling RK
Clin Gastroenterol Hepatol; 2008 Sep; 6(9):1036-40. PubMed ID: 18586559
[TBL] [Abstract][Full Text] [Related]
30. Mycophenolate mofetil as rescue treatment for autoimmune liver disease in children: a 5-year follow-up.
Aw MM; Dhawan A; Samyn M; Bargiota A; Mieli-Vergani G
J Hepatol; 2009 Jul; 51(1):156-60. PubMed ID: 19446911
[TBL] [Abstract][Full Text] [Related]
31. Successful treatment of severe refractory lupus hepatitis with mycophenolate mofetil.
Tagawa Y; Saito T; Takada K; Kawahata K; Kohsaka H
Lupus; 2016 Apr; 25(5):543-6. PubMed ID: 26762472
[TBL] [Abstract][Full Text] [Related]
32. Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naïve patients.
Zachou K; Gatselis N; Papadamou G; Rigopoulou EI; Dalekos GN
J Hepatol; 2011 Sep; 55(3):636-646. PubMed ID: 21238519
[TBL] [Abstract][Full Text] [Related]
33. [Mycophenolate mofetil, a possible new immunosuppresant].
Weberová J; Voboril R; Semecký V
Ceska Slov Farm; 2002 Sep; 51(5):220-5. PubMed ID: 12407919
[TBL] [Abstract][Full Text] [Related]
34. [Mycophenolate mofetil: an alternative treatment for refractory autoimmune hemolytic anemia in children].
Navarro Mingorance A; Jimenez García I; Galera Miñarro AM; Fuster Soler JL
An Pediatr (Barc); 2012 Jul; 77(1):64-5. PubMed ID: 22483537
[No Abstract] [Full Text] [Related]
35. Tacrolimus and Mycophenolate Mofetil as Second-Line Therapies for Pediatric Patients with Autoimmune Hepatitis.
Efe C; Taii HA; Ytting H; Aehling N; Bhanji RA; Hagström H; Purnak T; Muratori L; Werner M; Muratori P; Klintman D; Schiano TD; Montano-Loza AJ; Berg T; Larsen FS; Alkhouri N; Ozaslan E; Heneghan MA; Yoshida EM; Wahlin S
Dig Dis Sci; 2018 May; 63(5):1348-1354. PubMed ID: 29569003
[TBL] [Abstract][Full Text] [Related]
36. [Auto-immune hepatitis: therapeutic management].
Pariente A
Gastroenterol Clin Biol; 2003 May; 27(5 Suppl):B13-9. PubMed ID: 12843932
[No Abstract] [Full Text] [Related]
37. Mycophenolate mofetil: new applications for this immunosuppressant.
Moder KG
Ann Allergy Asthma Immunol; 2003 Jan; 90(1):15-19; quiz 20, 78. PubMed ID: 12546332
[TBL] [Abstract][Full Text] [Related]
38. Hepatitis C and mycophenolate mofetil--a clarification.
Fasola CG; Klintmalm GB
Liver Transpl; 2002 Apr; 8(4):411-2; author reply 412-3. PubMed ID: 11965590
[No Abstract] [Full Text] [Related]
39. Mycophenolate mofetil prevents development of urinary protein in autoimmune nephritis.
Takeda S; Takahashi M; Kusano E; Kobayashi E
Kidney Int; 2003 Jul; 64(1):365-6; author reply 366. PubMed ID: 12787433
[No Abstract] [Full Text] [Related]
40. Mycophenolate mofetil monotherapy for pemphigus vulgaris.
Bredlich RO; Grundmann-Kollmann M; Behrens S; Kerscher M; Peter RU
Br J Dermatol; 1999 Nov; 141(5):934. PubMed ID: 10583186
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
